Jnana Therapeutics is creating therapies to treat a wide variety of diseases by uncovering and targeting unique binding sites of highly validated protein targets. Chemoproteomics is facilitating drug discovery for previously inaccessible protein targets. Jnana has built a next-generation chemoproteomics platform, RAPID, to develop small molecule medicines for any target with unprecedented speed and efficiency. This approach is enabling Jnana to address a range of challenging target classes including SLC transporters, transcription factors and signaling scaffold proteins that are significant drivers of disease. Their lead candidate, JNT-517, is targeting a SLC transporter that plays a role in PKU.

<p>Jnana Therapeutics specializes in discovering and developing medicines to expand the universe of therapeutic impact. By combining deep drug discovery, development expertise and their proprietary technology, Jnana is unlocking highly validated but previously undruggable targets. Drug discovery involves use of Jnana’s chemoproteomic platform, Reactive Affinity Probe Interaction Discovery (RAPID), a proprietary ligand platform to identify small molecule binders irrespective of the target. The unbiased approach of RAPID allows challenging targets, such as transcription factors and helicases, to be investigated. By using their RAPID platform, Jnana is developing a pipeline targeting many rare genetic diseases, immune-mediated diseases and oncology.  </p>


Jnana Therapeutics

Research Associate II/Senior Research Associate, Drug Discovery

Scientist I/II, Early Discovery Biology

Research Associate, Early Discovery

Director, Toxicology

Scientist I/II, Medicinal Chemistry 

Don't see a perfect job? Apply opportunistically.

Jnana Therapeutics announced today that it has entered into an agreement to be acquired by Otsuka Pharmaceutical Co.

By bringing together the strength of Jnana’s RAPID platform with Otsuka’s global capabilities and resources, the proposed transaction will further enable the development of novel therapies for under-addressed diseases, including JNT-517 for PKU.

Upon completion of the acquisition later this year, Jnana will operate as a wholly owned subsidiary of Otsuka in Boston and continue its research and development.

Read more: https://bit.ly/4ftndW9 #biotechnology #biopharma #acquisition

Otsuka Pharmaceutical to Purchase Jnana Therapeutics for Over $1.1 Billion - ChemAnalyst

 Jnana Therapeutics to Participate in Upcoming Investor Conferences 

Jnana Therapeutics Closes $50 Million Series B Financing to Advance Lead PKU Program and Small Molecule Pipeline Based on Next Gen Chemoproteomic Platform - Business Wire

 Jnana closes $50M series B round, picks PKU as lead indication 

We’re excited to share the recipients of our 2024 awards, recognizing team members who have gone above and beyond.

Congrats to our entire team on a year of many achievements at Jnana!

[Pictured L to R: Susan Cantin, Josh Zweig, Long Nguyen, David Rogers, CPA, Devin Diedrich, Tamanna Asarpota, Frank Wu; not pictured recipients: Alex Fitz, Lea Rosskamp]

At #BIO2024 this week? Caroline Stark Beer, Chief Business Officer at Jnana, will be speaking on a panel titled “Exploring Deal-Making Options for Your Portfolio of Assets.”  
 
The session will examine and discuss business development opportunities across a range of deal structures. Under Caroline’s leadership, Jnana has entered into two strategic collaborations with Roche.  
 
More about the BIO panel here: https://bit.ly/4bKgZPv #biopharma #collaboration  

Exclusive: Jnana says pivotal trial of PKU pill could begin next year after promising results from a smaller study - Endpoints News

Otsuka Pharmaceutical’s Acquisition of Jnana Therapeutics - Global Legal Chronicle

 Roche partners with Jnana on SLC transporters 

 Treating pku with correctors of mammalian slc6a19 function 

Nirogy Therapeutics emerges with $16.5M to target metabolite transporters - Fierce Biotech

 Crystalline forms of a piperidine inhibitor of slc6a19 function 

 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION 

 Jnana Therapeutics’ Post 

 Dosing regimen for treating pku with a piperidine inhibitor of slc6a19 function 

Jnana Therapeutics Promotes Joel Barrish, Ph.D., to President - citybiz

Jnana Therapeutics Launches With $50 Million Series A Financing to Target the Cell’s Metabolic Gates - Business Wire

Otsuka pays $800M for Jnana and its clinical-stage PKU drug

Japan's Otsuka Pharma acquires American biotech startup Jnana Therapeutics for $1.1 B - BioSpectrum Asia

Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer - citybiz

Jnana closes $50 million financing to advance lead PKU program - The Pharma Letter

 Jnana Therapeutics Appoints George Vratsanos, M.D., as Chief Medical Officer and Head of R&D 

Jnana Therapeutics Presents New Positive Data from Phase - GlobeNewswire

 Small molecule inhibitors of mammalian slc6a19 function 

Jnana President Joanne Kotz to take on CEO role - Fierce Biotech

Our team enjoyed celebrating this year’s accomplishments at our recent holiday party. We look forward to making more progress toward developing transformative therapies for patients in the year ahead!

Jnana Therapeutics inks second collaboration with Swiss giant - The Pharma Letter

 New SLC6A19 inhibitors divulged in Jnana Therapeutics patents 

Jnana Therapeutics Enters Collaboration with Roche to Discover Novel Medicines that Target Key Regulators of Cellular Metabolism to Treat Immune-Mediated and Neurological Diseases - Business Wire

Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics - ET HealthWorld

Bain closes $3B biotech fund amid flurry of startup buyouts - BioPharma Dive

Jnana Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference - GlobeNewswire

Otsuka snaps up Jnana with its phenylketonuria drug for $800m - Pharmaceutical Technology

 Jnana Therapeutics inks second collaboration with Swiss giant 

 Jnana Therapeutics Announces Appointment of John Throup, Ph.D. as Senior Vice President, Head of Development 


              Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency
            

 Phenylketonuria Treatment Market Set to Surge at 7.8% CAGR, to Reach US$ 1.62 Billion by 2034: Fact.MR Report 

Jnana Therapeutics to Advance JNT-517 as Development Candidate and Potential First-in-Class Oral Treatment for PKU - Business Wire

Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. - GlobeNewswire

Otsuka to buy Boston chemoproteomics biotech for up to $1.1B - BioWorld Online

Roche, Jnana take aim at metabolite transporters in $40M discovery deal - Fierce Biotech

Watkins Advises Jnana Therapeutics in Acquisition by Otsuka Pharmaceutical - Latham & Watkins LLP

Jnana tops up with $107M series C, $2B Roche deal ...

Neurocrine, Jnana team up to discover CNS drugs

Otsuka Commits $800M in M&A Deal Bringing a Phase 3-Ready Metabolic Disorder Drug - MedCity News

SLC6A19 inhibitors disclosed in Jnana Therapeutics patent - BioWorld Online

 Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. 

Jnana Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

 Jnana Therapeutics Announces Appointment of Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer 



		
			
				May 10, 2024
							
		

		
			Freeline, Wugen & Jnana Secure EMA PRIME Designations For Novel Treatments
		

	

Japan’s Otsuka Pharma to pay up to $1.1-billion to acquire Jnana Therapeutics - The Globe and Mail

PKU is a rare, inherited metabolic disease that can cause progressive and severe neurological impairment and neuropsychological complications. There’s a critical need for a safe and efficacious treatment for individuals with PKU. This year, International PKU Day focuses on raising awareness about the lives of adults with PKU. 

Find out more at: https://www.espku.org/ #PKU #adultPKUawareness #PKUDAY2024 

Jnana Therapeutics Announces Second Collaboration with Roche to Address Challenging-to-Drug Targets in Cancer, Immune-Mediated and Neurological Diseases - PR Newswire

Jnana tops up with $107M series C, $2B Roche deal as it pushes metabolic asset into clinic - Fierce Biotech

Roche, Jnana take aim at metabolite transporters in $40M ...



		
			
				Feb 01, 2024
							
		

		
			Jnana says pivotal trial of PKU pill could begin next year after promising results from a smaller study
		

	

Jnana reports topline data from Phase Ia trial of PKU therapy - Clinical Trials Arena

Otsuka to buy Jnana in deal that may exceed $1 billion - The Pharma Letter

We’re at the E.S. PKU (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria) Conference this week. Stop by our exhibit table, and don’t miss our poster presentation featuring data on the efficacy and safety of JNT-517 from our Phase 1/2 study in adults with PKU. #ESPKU2024

Pfizer backs this women-led biotech in $107M Series C to develop pills for cancer, neurological diseases and rare disorders - Tech Funding News 

Jnana closes $107M series C round, banks $50M up front in second discovery Roche pact - BioWorld MedTech


								Sep 23, 2024
								Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
							

Jnana Therapeutics Announces Positive Clinical Proof of Concept Achieved with JNT-517, a Potential First-in-Class Oral Treatment for PKU - Yahoo Finance

 Jnana Therapeutics Raises $107M in Series C Funding 

 Jnana Therapeutics Closes $50M Series B Financing 

FierceBiotech names Jnana Therapeutics as one of its “Fierce 15” Biotech Companies of 2018 - Business Wire

Otsuka Pharmaceutical To Acquire Jnana Therapeutics For $800M - Contract Pharma

Jnana Therapeutics - The Pharma Letter

Jnana doses first subject in phenylketonuria therapy trial - Clinical Trials Arena

Jnana Therapeutics to Present Preclinical Data on its PKU Program at the 2023 Society for Inherited Metabolic Disorders Annual Meeting - Business Wire


								Sep 04, 2024
								Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
							

Otsuka pays $800M for Jnana Therapeutics and its clinical-stage PKU drug - Fierce Biotech

Jnana Therapeutics raises $107M for PKU program and announces new Roche partnership - Labiotech.eu

We are proud to announce that Jnana Therapeutics is now part of Otsuka Pharmaceutical Co., Ltd. Jnana will continue to be based in Boston and operate as a direct subsidiary of Otsuka America, Inc. 

We look forward to continuing our mission to develop small molecules against challenging-to-drug targets for under-addressed diseases and advancing JNT-517 into a pivotal Phase 3 study for PKU in early 2025. Read more: https://bit.ly/3ZD6b2q
 
#acquisition #pharmaceuticals #biotechnology 

Big Pharma-backed startup scores $107M, second Roche collab - The Business Journals

Latham & Watkins Advises Jnana Therapeutics in Acquisition by Otsuka Pharmaceutical - Latham & Watkins LLP

 The Week’s 10 Biggest Funding Rounds: Health And Biotech Land Big Week As DispatchHealth Leads 

Updated: Otsuka buys out small molecule drug discovery startup Jnana and its rare disease pill for $800M cash - Endpoints News



		
			
				Sep 23, 2024
							
		

		
			Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
		

	

Jnana deepens ties with Roche and grabs a new round of funding - BioPharma Dive

Today, we presented clinically meaningful, statistically significant results from the second-dose cohort of the Phase 1/2 clinical trial of JNT-517 in adults with phenylketonuria (PKU) at the Society for the Study of Inborn Errors of Metabolism 2024 Annual Symposium.

Based on these positive results, we plan to advance JNT-517 directly into a pivotal Phase 3 study in early 2025. Read more: https://bit.ly/47fmynI

#SSIEM24 #clinicaltrials #raredisease #PKU


Roche Doubles Down on Jnana’s RAPID Platform in $2B Deal (Updated) - BioSpace

Startup Jnana raises $50M to tackle elusive membrane protein targets - Fierce Biotech


								Aug 01, 2024
								Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
							

Jnana Therapeutics Appoints Doug Pagán, MBA, as Chief Financial Officer and Chief Operating Officer - citybiz

 Jnana Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference 

Phenylketonuria Market to Exhibit Significant Growth, - GlobeNewswire

Neurocrine, Jnana team up to discover CNS drugs - Fierce Biotech

Japan's Otsuka Pharma acquires American biotech startup Jnana Therapeutics for $1.1 B - BSA bureau

Otsuka Pharmaceutical to Acquire Jnana Therapeutics for $800M - Contract Pharma

 Roche, Jnana take aim at metabolite transporters in $40M discovery deal 

 Naphthyl-containing piperidine inhibitors of slc6a19 function 

Otsuka buys Jnana and PKU drug in $1.1bn deal - pharmaphorum

Jnana Therapeutics Announces Milestone Achieved Under First Collaboration with Roche - GlobeNewswire

Jnana Therapeutics tries to take on an untapped class of proteins - Chemical & Engineering News

Platform, PKU asset drive Otsuka’s $800M takeout of Jnana - BioCentury

Otsuka buys startup Jnana, adding to uptick in private biotech M&A - BioPharma Dive

Jnana Therapeutics describes new SLC6A19 inhibitors - BioWorld Online

Jnana Therapeutics

Business:

Drug notes:

About: